Hemolytic AnemiaNCT06708728
Study of Acquired Hemolytic Anemia in Adult Hospitalized Patients
An observational study of Hemolytic Anemia, run by Sohag University at 1 site in Egypt.
Trial summary
the goal of the study is to identify the most common etiological factors and analyze the clinical presentations and laboratory findings in hospitalized patients with acquired hemolytic anemia associated with non-neoplastic diseases. Read more about this study
- Who is it for?
- Ages 18 years and older
- Conditions the study is for
- Hemolytic Anemia
- What is being tested?
- blood samples
- How many people
- 60 participants
- Where
- 1 siteEgypt
- Study dates
- Dec 2024to Jun 2025
- Phase
- Observational
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 18 years and older
- All sexes
- No healthy volunteers
- Adult, Older adult
Study population: patients admitted in Internal Medicine department and Intermediate care unit at sohag university hospital
Who may be able to join
- Adults aged 18 years and older.
- Patients diagnosed with acquired hemolytic anemia.
- Patients must be hospitalized in the Internal Medicine department at the time of diagnosis of acquired hemolytic anemia during the study period
- Patients (or their legal representatives) must provide informed
Who cannot join
- Patients with underlying neoplastic diseases.
- Patients with hereditary hemolytic anemia.
- Patients or their representatives who do not consent to participate in the study.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Mahmoud I Yousef, Lecturer of Internal Medicine contact
About this study
Official title: Study of the Etiology, Clinical Features and Short Term Outcome of Acquired Hemolytic Anemia in Hospitalized Adult Patients with Non-Neoplastic Disease
the goal of the study is to identify the most common etiological factors and analyze the clinical presentations and laboratory findings in hospitalized patients with acquired hemolytic anemia associated with non-neoplastic diseases.
And to evaluate short-term outcomes, including morbidity and mortality rates, and to determine correlations between specific etiological factors and patient outcomes in these cases.
- Conditions
- Hemolytic Anemia
- Being tested
- blood samples
- Medical subject headings
- Anemia, Hemolytic
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
blood samplesOther
blood samples for CBC parameters , peripheral blood smear, bilirubin levels and kidney function tests
What is being measured
The primary outcome is the main question the study is designed to answer.
intensive care unit admission of the patients due to progression of the disease complications.
Primary outcome will be ICU admission due to progression of the disease complications.
Measured: through study completion, an average of 6 months
Secondary outcomes (1)
mortality within duration of hospital admission
Secondary outcome will be mortality within duration of hospital admission
Measured: through study completion, an average of 6 months
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted27 Nov 2024
- Study startDec 2024 (estimated)
- Primary completionJun 2025 (estimated)
- Study completionJun 2025 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Hemolytic AnemiaStudies of the same condition, open and under way.
- More trials run by Sohag UniversityThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Observational
- Observational model
- Cohort
- Time perspective
- Prospective
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- Sohag University
- Sponsor type
- University, hospital or other
- Responsible party
- Principal investigator, Ahmed Elsayed Mahmoud, Sohag University
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT06708728
- Sponsor's protocol ID
- AEMahmoud
- Status last verified
- Nov 2024
- First submitted
- 22 Nov 2024
- Last updated
- 27 Nov 2024
- Results posted
- No
- Data monitoring committee
- No
- FDA-regulated drug
- No
- FDA-regulated device
- No
Study at a glance
From the registry record, last updated by the sponsor on 27 Nov 2024. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Study of the Etiology, Clinical Features and Short Term Outcome of Acquired Hemolytic Anemia in Hospitalized Adult Patients with Non-Neoplastic Disease
- ClinicalTrials.gov ID
- NCT06708728
- Acronym / sponsor ID
- AEMahmoud
- Conditions
- Hemolytic Anemia
- Study type
- Observational
- Recruitment status
- Not yet recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- Sohag UniversityUniversity, hospital or other
- Study start
- Dec 2024 (estimated)
- Primary completion
- Jun 2025 (estimated)
- Study completion
- Jun 2025 (estimated)
- First posted
- 27 Nov 2024 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
the goal of the study is to identify the most common etiological factors and analyze the clinical presentations and laboratory findings in hospitalized patients with acquired hemolytic anemia associated with non-neoplastic diseases.
And to evaluate short-term outcomes, including morbidity and mortality rates, and to determine correlations between specific etiological factors and patient outcomes in these cases.
Study design
- Observational model
- Cohort
- Time perspective
- Prospective
Who may qualify
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult, Older adult
- Study population
- patients admitted in Internal Medicine department and Intermediate care unit at sohag university hospital
Key inclusion criteria (4 listed)
- Adults aged 18 years and older.
- Patients diagnosed with acquired hemolytic anemia.
- Patients must be hospitalized in the Internal Medicine department at the time of diagnosis of acquired hemolytic anemia during the study period
- Patients (or their legal representatives) must provide informed
Key exclusion criteria (3 listed)
- Patients with underlying neoplastic diseases.
- Patients with hereditary hemolytic anemia.
- Patients or their representatives who do not consent to participate in the study.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| blood samplesblood samples for CBC parameters , peripheral blood smear, bilirubin levels and kidney function tests | Other | – |
Primary outcome
intensive care unit admission of the patients due to progression of the disease complications.
Time frame: through study completion, an average of 6 months
Primary outcome will be ICU admission due to progression of the disease complications.
1 secondary outcome
mortality within duration of hospital admission
Time frame: through study completion, an average of 6 months
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 27 Nov 2024.
Related trials for Hemolytic Anemia
Active, not recruitingPhase 1
A Study of YTS109 Cell Injection in Subjects With Relapsed/Refractory Autoimmune Hemolytic Anemia
Autoimmune Hemolytic Anemia, Anti-CD19 STAR T-cell Therapy
Active, not recruitingPhase 1/2
Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Long-term Mitapivat Dosing in Subjects With Stable Sickle Cell Disease: An Extension of a Phase I Pilot Study of Mitapivat
Sickle Cell Disease, Hemolytic Anemia
RecruitingObservational study
HPC Offered for PRESERVE Expansion
Bone Marrow Transplant (BMT)
RecruitingPhase 2
Allogeneic Hematopoietic Stem Cell Transplantation for Severe Aplastic Anemia and Other Bone Marrow Failure Syndromes Using G-CSF Mobilized CD34+ Selected Hematopoietic Precursor Cells Co-Infused With a Reduced Dose of Non-Mobilized Donor T-cells
Severe Aplastic Anemia, MDS (Myelodysplastic Syndrome)
RecruitingPhase 1
Study to Evaluate the Safety and Tolerability of Escalating Doses of Fostamatinib in Subjects With Stable Sickle Cell Disease
Sickle Cell Disorders, Sickle Cell Disease
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Mahmoud I Yousef, Lecturer of Internal Medicine contact
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
An observational study of Hemolytic Anemia, run by Sohag University at 1 site in Egypt.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 27 Nov 2024. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Egypt. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ahmed E Mahmoud (02 01145943157, ahmed.elsayed95@med.sohag.edu.eg), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
intensive care unit admission of the patients due to progression of the disease complications. (time frame: through study completion, an average of 6 months). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 27 Nov 2024.